The Marseille Cancer Research Center celebrates its 50th anniversary ! -

Oct 2010 Bioorganic & medicinal chemistry letters

A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.


Wang M, Xia Y, Fan Y, Rocchi P, Qu F, Iovanna JL, Peng L


Novel arylethynyltriazole acyclonucleosides were synthesized and assessed for their anticancer activity on drug-resistant pancreatic cancer MiaPaCa-2 cells. One lead compound was found to have much more potent apoptosis-related antiproliferative effects than gemcitabine, the current first-line treatment for pancreatic cancer. Further investigations showed that this active compound did not inhibit DNA synthesis, which means that it does not resemble gemcitabine and may involve a different mechanism of action.

Read the article